Status:

COMPLETED

Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only

Lead Sponsor:

Amgen

Conditions:

Bone Metastases in Men With Hormone-Refractory Prostate Cancer

Bone Metastases in Subjects With Advanced Breast Cancer

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

The purpose of this study is to describe the safety and tolerability of denosumab administration as measured by adverse events, immunogenicity, and safety laboratory parameters in subjects who previou...

Eligibility Criteria

Inclusion

  • Subjects currently enrolled in study 20050103, 20050136, or 20050244
  • Subjects must sign the informed consent before any study specific procedures are performed

Exclusion

  • Developed sensitivity to mammalian cell derived drug products during the 20050103, 20050136, or 20050244 study
  • Currently receiving any unapproved investigational product other than denosumab
  • Subject is pregnant or breast feeding, or planning to become pregnant within 7 months after the end of treatment
  • Subject (male or female) is not willing to use 2 highly effective contraception during treatment and for 7 months (women) or 10 months (men) after the end of treatment
  • Male subject with a pregnant partner who is not willing to use a condom during treatment and for additional 10 months after the end of treatment
  • Any disorder that, in the opinion of the investigator, may compromise the ability of the subject to give written informed consent and/or comply with study procedures

Key Trial Info

Start Date :

July 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 1 2012

Estimated Enrollment :

35 Patients enrolled

Trial Details

Trial ID

NCT00950911

Start Date

July 1 2009

End Date

April 1 2012

Last Update

February 11 2014

Active Locations (17)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 5 (17 locations)

1

Research Site

Jindřichův Hradec, Czechia, 377 01

2

Research Site

Kroměříž, Czechia, 767 55

3

Research Site

Olomouc, Czechia, 775 20

4

Research Site

Prague, Czechia, 110 00